Developer docs
API playgroundTry for free, no card

Search company profiles

Kaiser Permanente Ventures

Full company profile

uuid0000qoe

Namestring
Kaiser Permanente Ventures
Legal namestring
Kaiser Permanente Ventures
Websiteurl
kpventures.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Kaiser Permanente Ventures (KPV) is the corporate venture capital arm of Kaiser Permanente, one of the largest integrated healthcare delivery systems in the United States. Founded in 1998 and co-founded by Chris Grant (now COO and EVP of The Permanente Federation), KPV invests in promising healthcare companies across Health Information Technology, Digital Health, Healthcare Services, Medical Devices, and Diagnostics & Precision Medicine. Over 25 years, the firm has executed more than 70 investments and deployed over $700 million in capital, building a portfolio that includes Abridge (generative AI for clinical documentation), Arine (AI medication optimization), Garner Health (provider quality analytics, valued at $2.74B at Series E), DexCare (patient demand platform), Freenome (multiomics cancer detection), Kate Farms (plant-based clinical nutrition), NOCD/Noto (behavioral health), Omada Health (virtual chronic care, IPO'd June 2025), and Vesta Healthcare (home-based virtual care).

The firm's core technology is its investment platform itself—a curated pipeline that leverages Kaiser Permanente's $93-101 billion integrated delivery network (24,605+ clinicians, 40 acute care hospitals, 618+ facilities, and 12.6 million members) as both a deal sourcing engine and a clinical validation asset. KPV does not develop products, sell services to external customers, or operate software platforms; it deploys equity capital into healthcare startups from early to growth stages. The firm is headquartered at 1 Kaiser Plaza, 22nd Floor, Oakland, CA, with a core team of approximately 7-8 investment professionals led by Managing Directors Amy Belt Raimundo and Daniel van den Bergh.

KPV's business model is that of a strategic corporate venture fund rather than an external AUM-gathering manager. Returns are generated through venture capital rates of return on equity investments, supplemented by the strategic value of piloting portfolio innovations inside the Kaiser Permanente system. Capital is sourced from the parent organization and is not externally raised, meaning KPV balances financial returns with strategic alignment to Kaiser Permanente's healthcare delivery mission. Distribution occurs through direct equity participation in priced funding rounds alongside tier-1 venture capital firms and peer strategic CVCs, with go-to-market executed via deep engagement with Kaiser Permanente operators and clinical leaders to identify pressing unmet needs.

Short descriptiontext

Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente, investing equity in early- to growth-stage healthcare companies across digital health, medical devices, diagnostics, and healthcare services. The firm leverages its parent's integrated delivery network to source deals and validate portfolio innovations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersOakland, United States
HQ citystring
Oakland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, strategic investments, corporate venture capital, healthcare innovation funding, medical technology investing
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Other Investment Pools and Funds5259
Product category
Healthcare Venture Capital
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeSubscription Recurring
Description

Strategic venture investing that generates venture capital rates of return while supporting Kaiser Permanente's healthcare mission. Invests in promising healthcare companies targeting areas of real need.

kpventures.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente that invests equity capital in promising healthcare companies spanning Health Information Technology, Digital Health, Healthcare Services, Medical Devices, and Diagnostics & Precision Medicine. The firm deploys capital from seed to growth stages and supports portfolio companies with strategic partnership opportunities, market validation, and access to Kaiser Permanente's clinical expertise and delivery network. It has made over 70 investments deploying more than $700 million in capital since 1998.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kaiser Permanente Ventures (KPV) is a corporate venture capital firm, not a product company. KPV was founded over 25 years ago and has invested in over 67 companies, targeting areas including Health Information Technology (Enterprise Solutions), Digital Health, Healthcare Services, Medical Devices, and Diagnostics and Precision Medicine. The firm leverages Kaiser Permanente's $93B integrated delivery system assets and capabilities to support innovative healthcare companies. KPV does not develop, sell, or distribute its own products or services to external customers. Notable portfolio companies include Abridge (generative AI for clinical documentation), Ordr (IoT security), DexCare (patient demand platform), NOCD (OCD treatment), Freenome (multiomics blood testing for early cancer detection), and Garner Health (provider quality analytics).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Kaiser Permanente Ventures operates in deep partnership with Kaiser Permanente, leveraging insights from 24,605+ clinicians, 40 hospitals, and 618+ healthcare facilities to identify and support innovative healthcare companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cigna Group's CVC focused on healthcare innovation; co-invested with KPV in NOCD. Directly comparable as a healthcare-focused strategic CVC investing from a payer/insurer parent.

TypeDirect peer
Description

Optum Ventures is UnitedHealth Group's CVC arm, investing across healthcare AI, digital health, and care delivery. Most directly comparable peer given similar integrated-payer-provider parent backing and broad healthcare mandate.

TypeDirect peer
Description

CVS Health's CVC arm investing in digital health and healthcare services; co-invested with KPV in Abridge. Highly comparable peer with overlapping healthcare thesis and similar strategic-investor model.

TypeDirect peer
Description

Mayo Clinic's CVC focused on medical devices, diagnostics, and digital health; co-invested with KPV in Ordr. Comparable as a leading integrated delivery system's CVC with clinical validation moats.

TypeDirect peer
Description

UPMC's venture arm investing in healthcare innovation from a large integrated delivery system parent. Comparable peer structure: IDS-backed CVC with clinical validation access for portfolio companies.

TypeDirect peer
Description

Providence Health's CVC; co-invested with KPV in DexCare. Direct peer as another IDS-backed healthcare CVC with similar stage range and thesis.

TypeDirect peer
Description

Mass General Brigham's venture/innovation fund; co-invested with KPV in Abridge and DexCare. Direct peer as another major academic health system CVC with similar investment profile.

TypeEmerging player
Description

Independent digital health-focused VC that co-led NOCD rounds with KPV. Comparable as a healthcare-specialized investor with overlapping thesis in consumer health and care navigation.

TypeEmerging player
Description

Healthcare-focused VC firm co-investing with KPV in DexCare rounds. Comparable as a sector-specialized VC with overlapping digital health thesis and co-investment relationship.

TypeEmerging player
Description

Healthcare-focused VC co-investing with KPV in DexCare rounds. Comparable as a healthcare-specialized investor with overlapping digital health and care delivery thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment140 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kaiser Permanente Ventures

Healthcare Venture Capitalkpventures.com

Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente, investing equity in early- to growth-stage healthcare companies across digital health, medical devices, diagnostics, and healthcare services. The firm leverages its parent's integrated delivery network to source deals and validate portfolio innovations.

What Kaiser Permanente Ventures does

Kaiser Permanente Ventures (KPV) is the corporate venture capital arm of Kaiser Permanente, one of the largest integrated healthcare delivery systems in the United States. Founded in 1998 and co-founded by Chris Grant (now COO and EVP of The Permanente Federation), KPV invests in promising healthcare companies across Health Information Technology, Digital Health, Healthcare Services, Medical Devices, and Diagnostics & Precision Medicine. Over 25 years, the firm has executed more than 70 investments and deployed over $700 million in capital, building a portfolio that includes Abridge (generative AI for clinical documentation), Arine (AI medication optimization), Garner Health (provider quality analytics, valued at $2.74B at Series E), DexCare (patient demand platform), Freenome (multiomics cancer detection), Kate Farms (plant-based clinical nutrition), NOCD/Noto (behavioral health), Omada Health (virtual chronic care, IPO'd June 2025), and Vesta Healthcare (home-based virtual care).

The firm's core technology is its investment platform itself—a curated pipeline that leverages Kaiser Permanente's $93-101 billion integrated delivery network (24,605+ clinicians, 40 acute care hospitals, 618+ facilities, and 12.6 million members) as both a deal sourcing engine and a clinical validation asset. KPV does not develop products, sell services to external customers, or operate software platforms; it deploys equity capital into healthcare startups from early to growth stages. The firm is headquartered at 1 Kaiser Plaza, 22nd Floor, Oakland, CA, with a core team of approximately 7-8 investment professionals led by Managing Directors Amy Belt Raimundo and Daniel van den Bergh.

KPV's business model is that of a strategic corporate venture fund rather than an external AUM-gathering manager. Returns are generated through venture capital rates of return on equity investments, supplemented by the strategic value of piloting portfolio innovations inside the Kaiser Permanente system. Capital is sourced from the parent organization and is not externally raised, meaning KPV balances financial returns with strategic alignment to Kaiser Permanente's healthcare delivery mission. Distribution occurs through direct equity participation in priced funding rounds alongside tier-1 venture capital firms and peer strategic CVCs, with go-to-market executed via deep engagement with Kaiser Permanente operators and clinical leaders to identify pressing unmet needs.

Kaiser Permanente Ventures firmographics

Firmographics
Name
Kaiser Permanente Ventures
Legal name
Kaiser Permanente Ventures
Website
https://kpventures.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
10,001+ employees
Short description
Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente, investing equity in early- to growth-stage healthcare companies across digital health, medical devices, diagnostics, and healthcare services. The firm leverages its parent's integrated delivery network to source deals and validate portfolio innovations.
Ownership category
akta.pro rank

Kaiser Permanente Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Other Investment Pools and Funds (5259)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Healthcare venture capital
  • Strategic investments
  • Corporate venture capital
  • Healthcare innovation funding
  • Medical technology investing

Where Kaiser Permanente Ventures is headquartered

Location

Headquarters

HQ city
Oakland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kaiser Permanente Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Revenue model

  1. Venture Capital Returns: Strategic venture investing that generates venture capital rates of return while supporting Kaiser Permanente's healthcare mission. Invests in promising healthcare companies targeting areas of real need.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Kaiser Permanente Ventures product offering

Product offering

Core offering

Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente that invests equity capital in promising healthcare companies spanning Health Information Technology, Digital Health, Healthcare Services, Medical Devices, and Diagnostics & Precision Medicine. The firm deploys capital from seed to growth stages and supports portfolio companies with strategic partnership opportunities, market validation, and access to Kaiser Permanente's clinical expertise and delivery network. It has made over 70 investments deploying more than $700 million in capital since 1998.

Product overview

Kaiser Permanente Ventures (KPV) is a corporate venture capital firm, not a product company. KPV was founded over 25 years ago and has invested in over 67 companies, targeting areas including Health Information Technology (Enterprise Solutions), Digital Health, Healthcare Services, Medical Devices, and Diagnostics and Precision Medicine. The firm leverages Kaiser Permanente's $93B integrated delivery system assets and capabilities to support innovative healthcare companies. KPV does not develop, sell, or distribute its own products or services to external customers. Notable portfolio companies include Abridge (generative AI for clinical documentation), Ordr (IoT security), DexCare (patient demand platform), NOCD (OCD treatment), Freenome (multiomics blood testing for early cancer detection), and Garner Health (provider quality analytics).

Differentiator

Problem solved

Functional benefit

Companies that use Kaiser Permanente Ventures

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Kaiser Permanente Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kaiser Permanente Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kaiser PermanenteflagshipStrategic or Co-development PartnerKaiser Permanente Ventures operates in deep partnership with Kaiser Permanente, leveraging insights from 24,605+ clinicians, 40 hospitals, and 618+ healthcare facilities to identify and support innovative healthcare companies.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Kaiser Permanente Ventures competitors and assessment

Company assessment

Direct peers

  • Cigna Ventures: Cigna Group's CVC focused on healthcare innovation; co-invested with KPV in NOCD. Directly comparable as a healthcare-focused strategic CVC investing from a payer/insurer parent.
  • Optum Ventures (UnitedHealth Group): Optum Ventures is UnitedHealth Group's CVC arm, investing across healthcare AI, digital health, and care delivery. Most directly comparable peer given similar integrated-payer-provider parent backing and broad healthcare mandate.
  • CVS Health Ventures: CVS Health's CVC arm investing in digital health and healthcare services; co-invested with KPV in Abridge. Highly comparable peer with overlapping healthcare thesis and similar strategic-investor model.
  • Mayo Clinic Ventures: Mayo Clinic's CVC focused on medical devices, diagnostics, and digital health; co-invested with KPV in Ordr. Comparable as a leading integrated delivery system's CVC with clinical validation moats.
  • UPMC Enterprises: UPMC's venture arm investing in healthcare innovation from a large integrated delivery system parent. Comparable peer structure: IDS-backed CVC with clinical validation access for portfolio companies.
  • Providence Ventures: Providence Health's CVC; co-invested with KPV in DexCare. Direct peer as another IDS-backed healthcare CVC with similar stage range and thesis.
  • Mass General Brigham AIDIF: Mass General Brigham's venture/innovation fund; co-invested with KPV in Abridge and DexCare. Direct peer as another major academic health system CVC with similar investment profile.

Emerging players

  • 7wireVentures: Independent digital health-focused VC that co-led NOCD rounds with KPV. Comparable as a healthcare-specialized investor with overlapping thesis in consumer health and care navigation.
  • Define Ventures: Healthcare-focused VC firm co-investing with KPV in DexCare rounds. Comparable as a sector-specialized VC with overlapping digital health thesis and co-investment relationship.
  • Frist Cressey Ventures: Healthcare-focused VC co-investing with KPV in DexCare rounds. Comparable as a healthcare-specialized investor with overlapping digital health and care delivery thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kaiser Permanente Ventures social profiles

Digital presence

Kaiser Permanente Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kaiser Permanente Ventures leadership team

Management profile

Number of profiles

Profiles8 records

Kaiser Permanente Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kaiser Permanente Ventures M&A and investment

M&A and investment

M&A

Investments140 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kaiser Permanente Ventures

What does Kaiser Permanente Ventures do?

Kaiser Permanente Ventures is the corporate venture capital arm of Kaiser Permanente that invests equity capital in promising healthcare companies spanning Health Information Technology, Digital Health, Healthcare Services, Medical Devices, and Diagnostics & Precision Medicine. The firm deploys capital from seed to growth stages and supports portfolio companies with strategic partnership opportunities, market validation, and access to Kaiser Permanente's clinical expertise and delivery network. It has made over 70 investments deploying more than $700 million in capital since 1998.

Is Kaiser Permanente Ventures a public or private company?

Kaiser Permanente Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Kaiser Permanente Ventures founded?

Kaiser Permanente Ventures was founded in 1998. It employs 10,001+ people.

Where is Kaiser Permanente Ventures based?

Kaiser Permanente Ventures is headquartered in Oakland, United States, in the North America region.

How does Kaiser Permanente Ventures make money?

One revenue line is on record: venture Capital Returns.

Who are Kaiser Permanente Ventures's main competitors?

Direct peers on record are Cigna Ventures, Optum Ventures (UnitedHealth Group), CVS Health Ventures, Mayo Clinic Ventures, UPMC Enterprises, Providence Ventures and Mass General Brigham AIDIF. Emerging players are 7wireVentures, Define Ventures and Frist Cressey Ventures.

Does Kaiser Permanente Ventures have an API?

No public API is recorded for Kaiser Permanente Ventures.

What industry is Kaiser Permanente Ventures in?

Kaiser Permanente Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 5259.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Health Tech WorldDigital care startup Garner secures US$100m fundingGarner Health has secured US$100 million in Series E funding for its digital care navigation platform serving employers. The funding round values the company at US$2.74 billion and was led by Index Ventures with participation from Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures. The company plans to use the capital to expand its provider quality platform, scale AI-powered product innovation, and grow its member base.//telecareaware.com/Short takes: Garner Health’s $100M Series E; Veradigm files financial reports for ’23/’24, moved to net loss; Rovex debuts autonomous in-hospital transport robotGarner Health raised $100 million in a Series E led by Index Ventures, valuing the company at $2.74 billion. Veradigm reported a $292 million net loss in 2024, down from $49 million income, and plans to file its 2025 10-K before year-end 2026. Rovex debuted an autonomous in-hospital transport robot, Rovi, piloted at BayCare Health System.MedCity NewsGarner Health Secures $100M to Connect Patients with High-Performing DoctorsGarner Health raised $100 million in Series E funding, led by Index Ventures, to expand its AI-driven platform that connects patients with high-performing doctors. The company, which has raised about $300 million and reached a $2.74 billion valuation, uses its dataset of over 60 billion medical records to identify quality providers. The financing will support its AI technology, including Garner Research Agent and Garner Member Assistant.Venture Capital Access OnlineGarner Health Closes $100 Million Series E at a $2.74B Valuation to Continue Addressing The Healthcare Quality and Cost GapGarner Health closed a $100 million Series E round led by Index Ventures, bringing its valuation to $2.74 billion. The company partners with nearly 800 customers and reports gross annual recurring revenue of about $200 million. The funding will support expansion of its AI-powered provider quality platform.FinSMEsGarner Health Raises $100M in Series E FundingGarner Health raised $100M in Series E funding at a $2.74 billion valuation, led by Index Ventures. The company will use the funds to expand its provider quality platform, scale AI innovation, and reach more members. Garner has nearly 800 clients and partners with major employers and health plans.BhbusinessThe Case for Going Niche in Behavioral HealthThis BHB+ opinion piece argues that new behavioral health providers should start with specific, narrow conditions rather than broad mental health services. The article cites NOCD as a leading example—a startup launched in 2018 focused exclusively on obsessive-compulsive disorder that raised approximately $84 million from investors including Cigna Ventures, 7wireVentures, Kaiser Permanente Ventures, and F-Prime Capital, and achieved its first month of positive EBITDA before expanding. In March 2025, NOCD announced the acquisition of trauma care provider Rebound Health and simultaneously restructured both companies under a new parent company called Noto, positioning itself as a specialty behavioral health provider for complex psychiatric conditions.ForbesThis Startup’s Clever Way To Cut Health Costs Helped It Hit A $1.4 Billion ValuationGarner Health, founded by former Bridgewater Associates analyst Nick Reber, has developed a data analytics platform that identifies high-quality, low-cost doctors using 320 million deidentified health insurance claims to help employers reduce healthcare spending. The company recently raised $118 million in Series C funding led by Kleiner Perkins, reaching a valuation of $1.35 billion, with participation from Redpoint, Maverick, and Kaiser Permanente Ventures. Garner Health reports saving clients an average of 12% on total healthcare costs while covering over 2.5 million members across more than 700 corporate customers.PR NewswireSureCo Raises $23 Million Series A From Health Velocity Capital and Kaiser Permanente Ventures to Meet Accelerating Demand for ICHRA Among Large EmployersSureCo, an Individual Coverage Health Reimbursement Arrangement administrator focused on large employers, completed a $23 million Series A funding round led by Health Velocity Capital with participation from Kaiser Permanente Ventures. The investment will enable SureCo to scale its technology platform and service team as the ICHRA market experiences accelerating momentum, with more than 44% of large employers considering the model for 2026 amid the steepest health insurance cost increases in 15 years.Venture Capital Access OnlineSureCo Raises $23 Million Series A From Health Velocity Capital and Kaiser Permanente Ventures to Meet Accelerating Demand for ICHRA Among Large EmployersSureCo, an Individual Coverage Health Reimbursement Arrangement administrator focused on large employers, has completed a $23 million Series A funding round led by Health Velocity Capital with participation from Kaiser Permanente Ventures. The investment will enable SureCo to scale its technology and expand its team to meet accelerating demand for ICHRA, with more than 44% of large employers reportedly considering the model for 2026 amid the steepest health insurance cost increases in 15 years. The funding round reflects industry confidence in ICHRA as a strategic growth opportunity, with carriers and benefits consultants now actively developing ICHRA strategies.Bhbusiness5 VC Firms to Watch in Behavioral HealthBehavioral Health Business highlights five VC firms to watch in 2025 for behavioral health investments: CVS Ventures, Autism Impact Fund, GV, .406 Ventures, and Kaiser Permanente Ventures, noting a projected uptick in venture capital activity after a two-year lull. The article explores how non-traditional investors like healthcare system and payer venture arms are increasingly active, with firms like CVS Ventures deploying significant capital as lead investor in companies such as Array Behavioral Health ($25M), Cortica ($40M), and SpectrumAi ($20M), while others like .406 Ventures have already seen successful exits through acquisitions like AbleTo to Optum for $470M.